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Summary
The lethal outcome of high-dose pulmonary virus in-
fection is thought to reflect high-level, sustained virus
replication and associated lung inflammation prior to
development of an adaptive immune response. Herein,
we demonstrate that the outcome of lethal/sublethal
influenza infection instead correlates with the initial
virus replication tempo. Furthermore, the magnitude
of early lung antiviral CD8+ T cell responses varies in-
verselywith inoculumdoseand is controlledby lymph-
node-residentdendritic cells (LNDC) through IL-12p40-
regulated FasL-dependent T cell apoptosis. These
results suggest that the inoculum dose and replica-
tion rate of a pathogen entering the respiratory tract
may regulate the strength of the adaptive immune re-
sponse, and the subsequent outcome of infection and
that LNDCmayserve as regulators (gatekeepers) in the
development of CD8+ T cell responses.
Introduction
The outcome of respiratory influenza virus infection
ranges from recovery and clearance of the virus to respi-
ratory distress and even death. Both innate and adaptive
immunity, as well as the extent of virus replication and
elimination, are thought to play important roles in deter-
mining the ultimate result of the influenza virus infection
(Zinkernagel, 1996). The clearance of influenza virus is
primarily mediated by influenza-specific CD8+ T cells
through Fas/FasL- and perforin-mediated destruction
of virus-infected cells (Topham et al., 1997). Mice lack-
ing CD8+ T cells (i.e., b2m
2/2 mice or CD8-antibody-
depleted mice) exhibit delayed clearance of influenza vi-
rus (Eichelberger et al., 1991). Furthermore, adoptive
transfer of CD8+ T cell effectors into B cell-deficient mice
protects mice from lethal influenza infections (Graham
and Braciale, 1997). Although influenza-specific CD8+
T cells can use FasL-mediated mechanisms to eliminate
Fas+ virus-infected cells (Lowin et al., 1994; Topham
et al., 1997), the activated T cells themselves are also
Fas+ and are therefore susceptible to FasL-mediated
killing. In fact, adoptive transfer of viral-antigen-loaded
FasL+ APC leads to elimination of virus-specific CD8+
T cells (Wolfe et al., 2002). These results suggest that
conditions that could trigger Fas/FasL-dependent elim-
*Correspondence: tjb2r@virginia.eduination of influenza-specific CD8+ T cells may result in in-
creased susceptibility to influenza-virus infection.
Induction of the CD8+ T cell response to respiratory vi-
ruses like influenza depends at least in part on the mat-
uration of viral-antigen-bearing respiratory dendritic
cells (RDC) and their migration from the lungs to the re-
gional peribronchial lymph nodes (PBLN) (Belz et al.,
2004; Legge and Braciale, 2003). Within the PBLN, the
RDC are thought to contribute to the activation of naive
influenza-specific T cells by presenting the viral antigen
to the T cells and providing secondary accessory inter-
actions (i.e., costimulatory molecules and growth fac-
tors) (Belz et al., 2004; Guermonprez et al., 2002; Legge
and Braciale, 2003). Furthermore, the nature of the cyto-
kine environment in the LN during the contact between
naive T cells and antigen-bearing DC influences the
type of the T cell response (Guermonprez et al., 2002).
For example, the accessory cytokine IL-12p70 is known
to upregulate CD25 expression on responding CD8+
T cells and increase T cell survival (Valenzuela et al.,
2002) as well as cytolytic activity (Bhardwaj et al., 1996).
IL-12p70 consists of a heterodimer of p40 and p35
chains (Trinchieri, 2003). However, the p40 subunit may
also be present as a monomer or a homodimer or may
be associated with p19 to form IL-23 (Trinchieri, 2003).
IL-12p40 homodimer was initially described as an IL-
12p70 signaling antagonist (Gillessen et al., 1995; Hein-
zel et al., 1997) because of its ability to selectively bind
the IL-12Rb1 receptor subunit with high affinity and
thereby inhibit IL-12p70 interaction with the signaling
IL-12Rb2 subunit and subsequent IL-12p70/IL-12R sig-
naling (Presky et al., 1996). The IL-12p40 subunit is se-
creted in 5–500-fold excess over IL-12p70 (D’Andrea
et al., 1992; Holscher, 2004) with approximately 20%–
40% of the IL-12p40 subunit present as the p40 homo-
dimer (Heinzel et al., 1997; Holscher, 2004), and defi-
ciency in p40 (i.e., in IL-12p402/2 mice) is associated
with enhanced CD8+ T cell cytolytic activity in the LN
(Magram et al., 1996). Although these findings support
the role of IL-12p40 homodimer as a competitive inhibi-
tor of IL-12p70 binding/signaling, other observations,
such as the stimulation of chemotactic response from
mononuclear phagocytes during virus infection (Russell
et al., 2003), indicate that p40 homodimers can directly
signal in immune cells (Heinzel et al., 1997; Holscher,
2004; Holscher et al., 2001). Thus it appears that IL-
12p40 can function in vivo both as a competitive inhibitor
as well as a signaling molecule for immune cells, presum-
ably through direct interaction with and signaling
through IL-12Rb1, resulting in differential effects of re-
ceptor engagement on various immune cell types
(Holscher, 2004; Kawashima et al., 1998; Zou et al., 1997).
In this report, we examine the regulatory function of
FasL and IL-12p40 in the generation of the CD8+ T cell
response to murine intranasal influenza infection over
different virus doses. We observed an inverse relation-
ship between virus inoculum size and the magnitude of
subsequent CD8+ T cell response. The generation of a
robust CD8+ T cell response was dependent upon
the downregulation of FasL expression on LNDC. We
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650Figure 1. Intranasal Influenza Virus Infections Inhibit Anti-Viral CD8+ T Cell Responses
BALB/c mice were infected intranasally with high (10 LD50, 1 LD50) or low (0.1 LD50, 0.01 LD50) dose of influenza virus and pulmonary virus titers
(A), and influenza-specific lung CD8+ T cell responses, assessed by IFNg intracellular staining and in vivo cytotoxicity (B), were determined at the
indicated time points following infection. The data in (A) represent the viral titer from three independent mice at each of the given times and in-
fection doses. The data in (B) are representative of two to three independent experiments with lung samples pooled from groups of mice (at least
four mice per group) and demonstrate that the pulmonary influenza-specific CD8 T cell response is significantly (p < 0.05) inhibited with increas-
ing inoculums of influenza virus. The data represent the average 6 standard deviation (SD) for each group.provide evidence that sustained production of IL-12p40
in the PBLN maintains elevated FasL on LNDC and that
elevated FasL expression on the LNDC results in in-
creased apoptosis of activated proliferating CD8+ T cells
in the PBLN and decreased effector CD8+ T cell genera-
tion. Furthermore, we demonstrate that in FasL-deficient
mice, there is markedly increased generation of acti-
vated effector CD8+ T cells and increased resistance to
high-dose influenza infection. These results suggest a
novel role for LN-resident DC in regulating the magnitude
of the CD8+ T cell response through IL-12p40-dependent
FasL expression.
Results
Pulmonary CD8+ T Cell Response to Influenza Virus
Infection
Both the magnitude and duration of virus replication in
the respiratory tract are considered to be critical predic-
tors of the outcome of infection with lytic respiratory vi-
ruses like type A influenza (Zinkernagel, 1996). To evalu-
ate the relationship between the initial lung virus load
and the development of an adaptive CD8+ T cell re-
sponse in the lungs, we investigated the kinetics of pul-
monary virus replication in mice infected intranasally
with relatively high (10 LD50, 1 LD50; with death in 5–7
days) or low doses (0.1 LD50, 0.01 LD50; with recovery
and virus elimination) of the mouse-adapted A/JAPAN/
305/57 (H2N2) influenza virus strain. Although we antic-
ipated that steady-state lung virus titers would reflect
the size of the intranasal inoculum used for infection,
this was not the case. Between days 2 and 4 postinfec-
tion (PI), lung virus titers reached comparable levels
(Figure 1A), independent of the initial virus inoculum,
suggesting that the lung virus titer did not directly corre-late with the outcome of infection (i.e., virus clearance/
recovery or death). Furthermore, the magnitude and
tempo of inflammatory-mediator gene expression in the
lungs (by gene array and/or RNase protection assay of
lung RNA) was commensurate with lung virus titers (data
not shown). However, an important difference among
groups receiving the different intranasal inocula was ev-
ident during the first 24–36 hr PI (Figure 1A, insert)—that
is, the initial tempo of virus replication and initial virus
load varied with inoculum size. Thus, increasing the in-
tranasal inoculum dose mimics the effect of infection
with a virus with increased virulence (i.e., more extensive
initial replication and a more rapid attainment of steady-
state replication in the lungs).
Because the induction of a robust antiviral CD8+ T cell
response has been documented to play a critical role in
pulmonary virus clearance and recovery from experi-
mental influenza infection (Eichelberger et al., 1991; Gra-
ham and Braciale, 1997; Topham et al., 1997), we next
evaluated the time course of the development of the
early pulmonary CD8+ T cell response as a function of in-
tranasal virus dose by intracellular cytokine (IFN-g) syn-
thesis and in vivo cytotoxicity (Figure 1B). Unexpect-
edly, the magnitude of the early CD8+ T cell response
in the lungs was inversely related to the initial inoculum
employed, suggesting that the early development (i.e.,
at days 4–7) of a robust lung CD8+ T cell response may
be critical for virus clearance and that the initial virus
replication tempo and early viral load influenced the de-
velopment of the CD8+ T cell response.
RDC Phenotype in the Lymph Nodes
The induction of a CD8+ T cell response to pulmonary
virus infection requires that naive virus-specific CD8+
T cell precursors entering secondary lymphoid organs
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gen presumably through T cell interaction with viral-
antigen-bearing RDC that have migrated from the respi-
ratory tract to the PBLN in response to lung infection
(Belz et al., 2004; Legge and Braciale, 2003). Using a re-
cently described in situ dye-labeling technique (Legge
and Braciale, 2003) to identify RDC that have migrated
to the PBLN in response to pulmonary infection, we
next evaluated the properties (e.g., tempo of migration,
cell-surface costimulatory marker and viral-antigen ex-
pression, and cytokine production) of migrant RDC and
draining LNDC after high- or low-dose infection. RDC
exhibited accelerated migration to the PBLN in re-
sponse to all virus doses (with a slight delay at the low-
est dose [0.01 LD50]) but only did so [as previously re-
ported, (Legge and Braciale, 2003)] during the initial
24–36 hr of infection (Figure S1 in the Supplemental
Data available with this article online)—that is, during
a timeframe when differences in the initial load of virus
in the lungs are evident for the different virus inocula
(Figure 1A, insert). As previously reported (Legge and
Braciale, 2003), migrant RDC, regardless of the initial in-
oculum dose, expressed the cell-surface phenotype of
mature, activated DC and had equivalent levels of costi-
mulatory molecules (i.e., CD40hi, CD80hi, CD86hi, Fig-
ure S2). In contrast, LNDC in the same PBLN retained
an immature phenotype (i.e., CD40lo, CD80lo, CD86lo)
up to 48 hr PI [(Legge and Braciale, 2003) and Figure S2].
Further examination of the RDC present within the PBLN
at the peak of RDC migration (18 hr PI) for viral-antigen
expression (assessed by FACS for conformationaly
intact influenza HA, NP, and the nonstructural NS1 pro-
teins) suggested that only migrant RDC, and not LNDC,
were virus infected but only after infection with higher in-
ocula doses (i.e., 10 LD50, 1 LD50) (Figures 2A–2B). This
difference in viral protein expression could reflect a dif-
ferential rate of infection (or the extent of infection) of
RDC in the lungs during the initial 24 hr following virus in-
fection—an important time for both initial virus replica-
tion/accumulation and accelerated RDC migration. Of
note, infectious virus was only detected in the PBLN
of a minority of high- or low-dose-infected recipients
(<50%) with virus titers typically ranging from 10–100
PFU/PBLN. The PBLN were free of infectious virus by
72 hr PI (unpublished data).
Recent evidence suggests that the multiplicity of in-
fection (MOI) of bone-marrow-derived DC by influenza
can affect DC IL-12 production and alter the polariza-
tion of allogeneic T cell responses (Oh and Eichelberger,
2000). We therefore evaluated intracellular IL-12p40 syn-
thesis by migrant RDC and LNDC in the PBLN following
high- and low-dose intranasal influenza-virus inocula-
tion. RDC and LNDC from the PBLN of uninfected and
high-dose-infected mice expressed significantly more
IL-12p40 than the corresponding DC isolated from
low-dose mice (Figure 2C). In order to assess the relative
contribution of IL-12p40-containing cytokines (i.e., IL-
12p40 monomer/homodimer, IL-12p70 [p40 + p35] and
IL-23 [p40 + p19]) to the overall p40 response in the
PBLN, we isolated PBLN from control (uninfected),
low-, and high-dose-infected mice at 24 hr PI. We then
cultured the intact PBLN in vitro for 48 hr and quanti-
tated the p40-containing cytokines released into culture
(Figure 2D). In agreement with the above intracellularcytokine data, total IL-12p40 secretion was higher (i.e.,
R2-fold) in the PBLN of uninfected and high-dose-
infected mice, but was produced at significantly lower
levels (p < 0.05) in the PBLN isolated from low-dose-
infected mice. It is noteworthy that whereas IL-12p70
secretion from cultured PBLN was comparable for in-
fected mice (note: no IL-12p70 was secreted from unin-
fected PBLN), IL-23 production was only increased in
cultured PBLN from low-dose-infected mice (p < 0.05).
Most importantly, IL-12p70 and IL-23 represented >95%
of the total IL-12p40 released from the low-dose PBLN,
whereas IL-12p40 monomer/homodimer was the pre-
dominant form of IL-12 secreted in high-dose and unin-
fected PBLN. These results raised the possibility that
the differential production of p40-containing ligands
could affect the magnitude of the CD8+ T cell response.
Activation and Expansion of Influenza-Specific CD8+
T Cells
Virus inoculum dose could affect either the efficiency of
activation of naive CD8+ T cell precursors or the fate of
activated T cells (or both). To evaluate the activation,
proliferative expansion, and ultimate fate of the CD8+
T cells responding to intranasal infection, we adoptively
transferred purified naive influenza HA-specific CD90.2+
Clone-4 (CL-4) TCR transgenic CD8+ T cells (Morgan
et al., 1996) (labeled in vitro prior to transfer with the
cell-division-sensitive dye CFSE to monitor initial T cell
activation/proliferation) into CD90.1+ mice 1 day prior
to high- or low-dose infection with influenza virus (Law-
rence and Braciale, 2004). Cell proliferation and fate was
monitored by flow cytometry. The initial amount of CL-4
T cells in the PBLN at day 1–2 PI was comparable after
high- or low-dose infection (Figure 3A). Likewise, in the
PBLN following both high- and low-dose infections, CL-
4 T cells demonstrated a similar level of early-activation
marker expression (i.e., CD25, CD69, data not shown)
with the onset of T cell proliferation (dye dilution) occur-
ring at days 2–3 PI (Figure 3A). For both infected cohorts,
the extent of transferred T cell proliferation was similar
with high-dose animals demonstrating somewhat more
extensive cell division (consistent with the more ex-
tensive viral replication during the first 24–36 hr PI—
Figure 1A, insert). Although initial CD8+ T cell prolifera-
tion was not affected by inoculum size, total CD8+
T cell accumulation in the draining PBLN differed signif-
icantly (p < 0.05) between the 2 infected groups with ap-
proximately a 2-fold-higher number of activated T cells
present in the PBLN of the low-dose-infected recipients
by day 4 PI (Figure 3B, left panel). This finding suggested
that continued accumulation of proliferating CD8+ T cells
at day 4 was altered in the high-dose-infected mice. The
impact of this difference in CD8+ T cell accumulation was
most evident when the activated T cells migrating from
the PBLN to the lungs at day 4 PI were quantitated (Fig-
ure 3B, right panel). At day 4 of infection, lungs of low-
dose-infected mice contained >5-fold more (p < 0.05) re-
sponding T cells than high-dose infected mice.
Because initial T cell activation/proliferation in the
PBLN was comparable after high- or low-dose infection,
a difference in the extent of activated T cell apoptosis in
the LN might account for the difference in total T cell ac-
cumulation in the PBLN at day 4 PI. Indeed, although ac-
tivated T cells from both cohorts expressed comparable
Immunity
652Figure 2. Differential Influenza Protein and IL-12 Expression by DC after High- and Low-Dose Influenza-Virus Infections
(A and B) Viral protein expression by migrating CFSE+ RDC (A) following the indicated inoculum dose and CFSE2 LNDC ([B], after 1 LD50 shown)
within the PBLN was determined at 18 hr PI by flow cytometry for influenza HA, NP, and NS1 proteins. RDC within the PBLN displayed a mature
phenotype (CD40hi, CD80hi, CD86hi), whereas LNDC, which were influenza protein negative at all doses, maintained an immature phenotype dur-
ing the first 48 hr of infection (Figure S2).
(C) The production of IL-12p40 by RDC (top panel) or LNDC (lower panel) was measured by intracellular cytokine staining from PBLN of unin-
fected (filled, light gray), high-dose-infected (10 LD50; dotted line), or low-dose-infected (0.1 LD50; black line) mice at 18 hr PI. Staining with
the isotype control was included for comparison (filled, dark gray).
(D) The levels of secreted IL-12p40, IL-12p70, and IL-23 from cultured intact PBLN obtained from high-dose, low-dose, and uninfected mice at 24
hr PI were measured by ELISA (and confirmed by BioPlex Suspension Array System [BioRad], data not shown) after 48 hr of in vitro culture. IL-
12p40 monomer and homodimer levels were calculated by subtracting the IL-12p70 and IL-23 values from the total IL-12p40 amounts. The data
in (A–D) are representative of two to three independent experiments with PBLN samples pooled from groups of mice (at least four mice per
group). The data in (D) represent the average 6 SD for each group.levels of CD95 (Figure 3D), the CD8+ T cells from high-
dose-infected mice demonstrated increased apoptosis
(p < 0.06) within the PBLN by day 4 PI (Figure 3C)—which
is the critical point when proliferating T cells migrate
from the PBLN to the lungs. Although the difference in
the apoptosis rate of proliferating T cells at day 4 was not
large (i.e., approximately 52% versus 35% Annexin V+,
T cells for high and low dose, respectively, Figure 3C),
the cumulative impact (in the PBLN and lungs) of in-
creased apoptosis of the proliferating T cells responding
to high-dose infection was substantial (Figure 3B). Over-
all, these data suggest that differences in the magnitude
of the pulmonary CD8+ T cell response to infection re-
flect regulation not at the level of CD8+ T cell induc-tion/activation but, at least in part, at the level of T cell
viability during proliferation/differentiation in the PBLN.
Because our above results demonstrated differences
in IL-12 production by PBLN-DC, and IL-12 has been re-
ported to be an important regulator of FasL (CD178) ex-
pression (Gavrilescu and Denkers, 2003; Lee et al.,
2003), we next examined FasL expression in the PBLN
during the critical day 3–4 window following high- and
low-dose influenza infection. Whereas CD11c2 cells lack
surface FasL, LNDC within PBLN excised from mice at
day 3 after high-dose infection expressed FasL (Figure
3E). A direct comparison of FasL levels on LNDC from
the PBLN of uninfected, high-, and low-dose influenza-
infected mice (Figure 3E) revealed that LNDC from the
FasL+ DC Regulation of Viral CD8 T Cell Immunity
653Figure 3. Naive Influenza-Specific T Cells Are Activated, but Are Quickly Driven into Apoptosis by LNDC within the PBLN after Lethal Infections
(A) CD90.2+CD8+-purified CFSE-labeled HA-specific CL-4 T cells (107) were adoptively transferred intravenously into BALB/c CD90.1+ congenic
recipients. Twenty-four hours later, the mice were given intranasally a high- (10 LD50) or low-dose (0.1 LD50) inoculum of influenza virus and T cell
proliferation, i.e., CFSE dilution assessed on days 1–3 PI. Data display the proliferative response of CD90.2+ gated cells.
(B) The number of viable (Annexin V2) donor CD90.2+ CL-4 cells in the PBLN and lungs after influenza infection was calculated by multiplying the
percentage of 7-AAD2CD90.2+ cells by the total viable cell counts (trypan blue exclusion) in PBLN/Lung suspensions. The number of Annexin V+,
7-AAD2CD90.2+ cells was then subtracted to yield the total number of healthy cells. The data in (B) represent the average6 SD for each group.
(C) Apoptosis of CL-4 transferred cells was evaluated by 7-AAD/Annexin V staining of cells from PBLN excised on days 3–4 PI. Representative
data on the apoptosis marker expression by CD90.2+ CFSE+ gated cells (C) are shown.
(D) Three days PI the PBLN were removed, and cells were stained for CD95 expression (thick line) and analyzed by flow cytometry. The panels
represent CD90.2+ CFSE+ CL-4 gated cells. Cells stained with hamster IgG (an isotype control antibody for CD95 staining, thin line) were included
as a control.
(E) BALB/c mice were infected as in Figure 2 (i.e., no T cell transfer), and at 3 days PI the PBLN cells were analyzed for FasL (CD178) expression by
flow cytometry. The expression level of FasL on CD11c+ DC following high-dose (10 LD50) infection (filled, light gray) and on the remaining
CD11c2PBLN cell populations (filled, dark gray) are indicated. Staining with an Armenian hamster IgG1, k isotype control was included as a con-
trol (black line).
(F) The mean fluorescence intensity of FasL staining of CD11c+ DC from PBLN of uninfected, 10 LD50-infected, and 0.1 LD50-infected mice at day
3 PI are shown. Staining with an Armenian hamster IgG1, k isotype control was included as a control [Isotype].
Data in (A–F) are representative of three independent experiments with pooled cells from at least three mice.PBLN of high-dose-infected mice expressed moder-
ately high levels of FasL similar to PBLN DC from unin-
fected mice, whereas LNDC from low-dose-infected an-
imals expressed little cell-surface FasL (i.e., comparable
to the isotype control antibody). FasL expression on
other cell types within the infected donor PBLN (e.g.,
B cells, T cells, NK cells, etc.) was restricted to a small
fraction of these LN cell populations and did not vary as
a function of intranasal virus dose employed (data not
shown). Because FasL expression by DC has been hypo-
thesized to regulate the magnitude of T cell responsesthrough FasL (on DC)-dependent/Fas (on T cells)-
dependent T cell apoptosis (Lu et al., 1997; Suss and
Shortman, 1996), control of the magnitude of the early
CD8+ T cell response might be mediated through such
a mechanism.
Impact of Lymph Node Expression of FasL
To assess the impact of FasL expression and IL-12 lev-
els in the PBLN on T cell apoptosis, we developed an
in vitro system wherein PBLN from CFSE-labeled CL-4
T cell recipient mice are excised 48 hr PI and incubated
Immunity
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capitulates Results from LN Analyzed Di-
rectly Ex Vivo after Influenza Virus Infection
(A) BALB/c CD90.1+ mice received 107,
CFSE-labeled CD90.2+ CD8a purified CL-4
T cells by adoptive transfer. Twenty-four
hours later, the mice were infected with a
low (0.1 LD50) dose of influenza virus. At
48 hr PI, PBLN were removed and either di-
rectly fixed and stained (48 hr ex vivo) or cul-
tured intact in 95%O2-5%CO2 (48 hr + 24 hr
in vitro [+O2]) or 5% CO2/balanced air (48 hr +
24 hr in vitro [no O2]) for 24 hr and then stained
for CD90.2 expression. Proliferation (CFSE
dilution) of CD90.2+ CL-4 T cells was then an-
alyzed by flow cytometry. As a control, PBLN
were removed from a second set of mice at
72 hr PI (72 hr ex vivo) and stained directly
ex vivo for CD90.2 expression.
(B) In companion experiments, PBLN were
excised at 48 hr post a high (10 LD50) or a
low dose (0.1 LD50) of influenza-virus infec-
tion and then cultured intact, as above, under
high O2 tension. After 48 hr of culture (i.e., day
4 PI), apoptosis (7-AAD/Annexin V staining)
of CD90.2+CFSE+Clone-4 T cells was mea-
sured.
Data in (A and B) are representative of four
experiments with pooled cells from at least
four PBLN donor mice.intact for 48 hr in vitro under conditions of high 02 ten-
sion to recapitulate the proliferative response of CL-4
T cells in the PBLN in vivo (Figure 4A). Accordingly, after
high- and low-dose infection, we detected more exten-
sive division (dye dilution) of transferred CFSE-labeled
CL-4 T cells and a greater percentage of apoptotic CL-4
T cells (Figure 4B) (as well as lower overall T cell recovery)
within excised intact PBLN from high-dose-infected re-
cipients than for the corresponding PBLN CL-4 T cell
population from low-dose-infected recipients. Impor-
tantly, the low recovery of CL-4 T cells from cultured
high-dose PBLN could be reversed by addition of solu-
ble Fas-Fc to block Fas/FasL interactions and apoptosis
(data not shown) during the 48 hr incubation period
in vitro (Figure 5A). Neutralization of IL-12p40 in intact
cultured PBLN, with anti-IL-12p40 antibody, likewise
dramatically increased the yield of activated CL-4 T cells
from both high- and low-dose-cultured PBLN, whereas
addition of exogenous rmIL-12p40 homodimer to cul-
tured PBLN markedly decreased T cell recovery (Fig-
ure 5A). Further evidence for an IL-12p40-dependent
regulation of FasL expression on resident LNDC came
from companion studies, which demonstrated that
short-term (24 hr) incubation of intact PBLN from unin-
fected mice in the presence of neutralizing anti-IL-
12p40 antibody significantly decreased FasL expression
on LNDC (Figure 5B), whereas IL-12p40 homodimer ad-
dition significantly increased FasL expression on LNDC
in PBLN from low-dose-infected mice (Figure 5C).Influenza-Specific CD8+ T Cells in FasL2/2 Mice
To directly determine the impact of FasL on the fate of
CD8+ T cells responding to high- or low-dose infection,
we transferred CFSE labeled CL-4 T cells into wild-
type or congenic FasL-deficient (FasL2/2) mice and then
evaluated the proliferative response and accumulation
of activated CL-4 T cells in the PBLN 4 days PI. Consis-
tent with the above results, CL-4 T cells from both in-
fected groups underwent more extensive proliferation in
the environment of the FasL-deficient PBLN (data not
shown). Strikingly, whereas FasL deficiency resulted in
a modest increase in total PBLN CL-4 T cell accumula-
tion after low-dose infection, the FasL-deficient PBLN
environment demonstrated a greater-than-5-fold in-
crease (p < 0.01) in CD8+ T cells numbers when com-
pared to FasL+/+ wild-type PBLN during high-dose infec-
tions (Figure 6). Furthermore, because CL-4 T cells can
express both FasL and Fas in FasL2/2 recipients, apo-
ptosis mediated by T cell-to-T cell interactions (i.e.,
FasL/Fas-dependent) does not explain the apoptosis
of influenza-specific T cells during high-dose influenza
infections of wild-type mice.
These results suggested that LNDC FasL expression
may likewise influence the outcome of infection. To
examine this possibility, we analyzed the morbidity
(weight reduction) and survival of wild-type and FasL2/2-
deficient mice after intranasal infection with differing
doses of influenza virus. The LD50 for intranasal infection
of FasL2/2 mice was greater than 100-fold higher than
FasL+ DC Regulation of Viral CD8 T Cell Immunity
655Figure 5. Blockade of FasL or IL-12p40 Neutralization Inhibits Apoptosis and Promotes Influenza CD8+ T Cell Expansion
(A) In companion experiments to those described in Figure 4, rmIL-12p40, rmIL-12p70, anti-IL-12p40 mAb, Fas-Fc, anti-Fas mAb, human IgG
isotype control Ab, or rat IgG2a isotype control mAb were added to the wells during the 48 hr in vitro culture of intact PBLN. Cells were then
harvested and evaluated for apoptosis (7-AAD/Annexin V staining) and CD90.2 expression, and the cell number was determined by multiplying
the percentage of viable CD90.2+7-AAD2 cells by the total viable number of PBLN cells after LN dissociation. These numbers were then stan-
dardized to the number of cells in 0.1 LD50 PBLN cultures [i.e., (PBLN culture cell #/0.1LD50 cell #)3 100]. Addition of human IgG isotype control
Ab or rat IgG2a to the LN cultures did not alter CL-4 T cell apoptosis (data not shown).
(B) PBLN from uninfected BALB/c mice were removed and cultured intact in vitro 24 hr with anti-mouse IL-12p40 (black line), rat IgG2a (an iso-
type control for the anti-IL-12 p40 mAb [dotted line]) or media alone for 24 hr (filled light gray).
(C) PBLN from 0.1 LD50-infected mice were removed and cultured intact in vitro with rIL-12p40 homodimer (filled light gray) or media (black line).
After 24 hr (B and C), the cells were stained for FasL expression and analyzed by flow cytometry. Staining with an isotype control antibody
(a control for anti-FasL) was included for reference (dark gray [B and C]). The data in (A–C) are representative of at least two experiments
with pooled intact lymph nodes from eight mice.Figure 6. Infection of FasL-Deficient Mice Restores CD8+ T Cell Ex-
pansion after High-Dose Influenza Infection
BALB/c (WT, open histogram) and FasL-deficient congenic CPt.C3-
Tnfsf6gld/J (FasL2/2, filled histogram) recipients of 107 CFSE-labeled
CL-4 T cells were infected intranasally 24 hr later with high (10 LD50)
or low (0.1 LD50) doses of influenza virus. Four days PI the PBLN
were harvested, and the extent of proliferation (i.e., CFSE dilution,
see Figure S3) and the total CL-4 T cell numbers accumulated were
determined. Cell numbers within the PBLN were determined by
([total PBLN cell count] 3 [percentage of cells that were CD8a+
CSFE+ and/or Granzyme B+], see Figure S3). Data are representative
of two experiments with pooled cells from two mice and represent
the average 6 SD for each group.that of age-matched wild-type control mice (5.5 3 106
EIU versus 3.53 104 EIU for FasL2/2 and wild-type mice,
respectively) (Figure 7A), and FasL2/2 mice displayed
decreased morbidity (weight loss) compared to control
mice during infection (Figure 7B).
Discussion
Our findings suggest a novel mechanism for the control
of CD8+ T cell responses to antigen (pathogen) exposure
at peripheral sites (e.g., the respiratory tract)—that is,
regulation of the magnitude of the CD8+ T cell response
within the draining LN (e.g., PBLN) through LNDC FasL-
dependent apoptosis of responding T cells. Accord-
ingly, migrant DC (e.g., RDC) entering the draining LN
from the periphery would serve the dual function of
both transporting and presenting antigen (directly or in-
directly) to naive CD8+ T cells and regulating FasL ex-
pression on LNDC by modulating IL-12p40 levels within
the draining LN.
The operation of this FasL-dependent regulatory
mechanism is likely to be intimately tied to the architec-
tural integrity of the intact LN, the importance of which in
T cell activation/differentiation has recently been sug-
gested (Germain and Jenkins, 2004; Gretz et al., 1997).
Thus, in our model system, the interaction of naive
virus-specific CD8+ T cells with migrant antigen-bearing
RDC in the LN at the cortical ridge (Katakai et al., 2004)
shortly after T cell transit through the HEV would result
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656Figure 7. FasL-Deficient Mice Exhibit En-
hanced Resistance to Infection
C57Bl/6J and FasL-deficient congenic
B6Smn.C3-Tnfsf6gld/J mice were infected in-
tranasally with either 2.35 3 106, 2.35 3 105,
2.35 3 104, 2.35 3 103, or 1.05 3 103 EIU of
A/JAPAN/305/57, and the survival (A) and the
morbidity (B) (as measured by weight loss) of
the mice was monitored daily. The LD50 was
then determined by the Reed-Muench accu-
mulative method. Shown are the survival
curves for wild-type (WT, -:-) and FasL2/2
(-O-) mice infected at 2.35 3 106 and 2.35 3
105 EID50 units dose respectively. Similar
results were obtained with BALB/c and
CPt.C3-Tnfsf6gld/J mice (data not shown).in initial T cell activation (Bajenoff et al., 2003; Gretz
et al., 1997). We speculate that the subsequent encoun-
ter of activated Fas+CD8+ T cells with FasL+ LNDC as the
T cells transit from the LN cortex through dense LNDC
networks (Lindquist et al., 2004) to the medulla would
dictate the fate of the T cells, i.e., apoptosis or full differ-
entiation and egress from the PBLN to the infected
lungs. Whether this T cell/LNDC interaction is depen-
dent on TCR engagement and recognition of foreign
(viral) or self MHC complexes on LNDC remains to be de-
termined, although FasL expression at immunologically
privileged sites (Aoki et al., 2001; Green and Ferguson,
2001) or on adoptively transferred DC (Wolfe et al.,
2002; Wu et al., 2001) has been shown to result in the
elimination of activated CD8+ T cells—in the latter instan-
ces by an antigen-dependent mechanism. Although, in
our study, the difference in the rate of T cell apoptosis
demonstrable in the PBLN of high- and low-dose-
infected animals fluctuated from experiment to experi-
ment, the overall trend in the apoptosis rate between
the high- and low-dose-infected groups and the associ-
ation between apoptosis and the FasL expression level
by LNDC favors this mechanism.
Either migrant mature RDC or LNDC (or both, see Belz
et al., 2004) could serve as the APC for naive CD8+ T cell
activation in the PBLN. Because, unlike migrant RDC,
LNDC display low levels of costimulatory ligands during
the initial phase (i.e., day 1–2 PI) of CD8+ T cell activation,
LNDC are likely to be less efficient on a per-cell basis as
APC (compared to migrant RDC) (Mellman and Stein-
man, 2001). In contrast, after high-dose infection, it is
the FasL+ LNDC that likely regulate apoptosis of acti-
vated proliferating CD8+ T cells at day 3–4 PI because
migrant RDC in the PBLN are FasL2 and have been elim-
inated from the PBLN at this time. Furthermore, in vitro
coculture of LNDC from the PBLN of high-dose-infected
mice (day 3 PI) with activated, proliferating CD8+ T cells
results in the increased apoptosis of the T cells in culture
(K.L.L. and T.J.B., unpublished data), further implicating
FasL+ LNDC in controlling CD8+ T cell proliferative ex-
pansion. As noted above, a requirement for cognate (an-
tigen-specific) T cell/LNDC interaction in apoptosis in-
duction has not yet been determined. If FasL+ LNDC/T
cell interaction resulting in T cell apoptosis is cognate(like naive T cell activation by DC), then the activation
state of the CD8+ T cell must dictate its susceptibility
to apoptosis.
Our results suggest that IL-12p40 is an important reg-
ulator of FasL expression and therefore of CD8+ T cell re-
sponses in the PBLN. Migrant RDC would appear to be
the likely candidate cell type regulating IL-12p40 levels
in the PBLN because RDC represent >90% of the cells
migrating from the lungs to the PBLN after influenza in-
fection (Legge and Braciale, 2003). This point awaits ex-
perimental verification. Furthermore, our results indicate
that the p40 expression level by RDC in the PLBN is de-
pendent on the type of antigen exposure in the periphery
(in this instance, intranasal inoculum dose) and that
a similar profile/level of p40 expression is acquired by
LNDC resident in the PBLN (Figure 2C). In this manner,
the level of p40 expression can be maintained even after
the loss of the RDC in the PBLN after the first 24–36 hr of
infection (Legge and Braciale, 2003).
Our finding that infection of migrant RDC was only de-
monstrable after high-dose infection (Figure 2A) pro-
vides additional support for the likely role of RDC in reg-
ulating PBLN IL-12p40 levels because infection of RDC
could alter their capacity to control the levels and form
of IL-12p40 expressed within PBLN and, in turn, the
FasL expression on LNDC. Whether this finding also im-
plies that with low-dose infection RDC deliver viral anti-
gen by crosspresentation (Belz et al., 2004; Norbury
et al., 2004) is uncertain because the MOI of RDC in
the respiratory tract rather than RDC infection per se
during the early phase of pulmonary virus replication
(Figure 1A) could impact on both the magnitude of viral
protein expression by migrant RDC as well as their func-
tion in the LN.
This report also highlights a heretofore-underappreci-
ated effect of pathogen-inoculum dose on the outcome
of pulmonary infection, i.e., increasing inhibition/sup-
pression of an early adaptive immune response with in-
creasing virus dose. These findings, when coupled with
the transient nature of RDC migration following influ-
enza- virus infection (Legge and Braciale, 2003), suggest
that the initial viral load in the lungs is a critical regulator
of the phenotype of the RDC and hence the adaptive
immune response. These results further suggest that
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pathogens) that can rapidly reach high lung titers within
the first 24 hr PI might also be able to negatively regulate
the adaptive response through their interactions with or
infection of RDC.
In conclusion, we have described a mechanism for
control of the development of an adaptive immune re-
sponse to respiratory pathogens where LNDC (through
regulated expression of FasL) serve as gatekeepers
modulating the magnitude of the host CD8+ T cell re-
sponse. This gatekeeper function of LNDC was revealed
through analysis of the impact of pathogen inoculum
dose—but the regulation of this FasL/IL-12p40 axis
may be important in the design of vaccine candidates
administered at peripheral sites. Whether this FasL/IL-
12p40 regulatory circuit plays a role in regulating the
adaptive immune responses to self constituents (Juedes
and von Herrath, 2003; Moser, 2003) is uncertain and
awaits additional experimental analysis.
Experimental Procedures
Mice
BALB/cAnNTac (H-2d) mice were purchased from Taconic Labora-
tory Animals and Services. BALB/c thy1.1 congenic mice were a
kind gift of Dr. Richard I. Enelow, Yale University. CPt.C3-Tnfsf6gld/J,
B6Smn.C3-Tnfsf6gld/J, and C57Bl/6J mice were purchased from
The Jackson Laboratory. All experiments were preformed in accor-
dance with regulatory standards and guidelines and were approved
by institutional (University of Virginia and University of Iowa) Animal
Care and Use Committees.
Virus Infection
Groups of 8-week-old BALB/c and CPt.C3-Tnfsf6gld/J mice were
given either a 10 LD50 (5.875 3 10
5 EIU), 1 LD50 (5.875 3 10
4 EIU),
0.1 LD50 (5.875 3 10
3 EIU), or 0.01 LD50 (5.875 3 10
2 EIU) dose of
mouse-adapted A/JAPAN/305/57 in Iscove’s media intranasally fol-
lowing anesthesia with methoxyflurane. For determination of mor-
bidity, mortality, and LD50, age-matched B6Smn.C3-Tnfsf6
gld/J
and C57Bl/6J were infected intranasally with 2.353 106, 2.353 105,
2.353 104, 2.353 103, or 1.053 103 EIU of A/JAPAN/305/57.
Lung Virus Titer
Lungs from infected mice were rapidly homogenized, snap frozen,
and stored at280ºC. Subsequently, serial dilutions of homogenized
lungs were injected into groups of 10-day-old fertile eggs, and then
the eggs were incubated for an additional 48 hr at 35ºC. Virus titer
was determined and quantified by hemagglutination assay of allan-
toic fluid with the Reed-Muench method.
Peptides
The peptides used in this study, HA204–212 (LYQNVGTYV), HA529–537
(IYATVAGSL), and NP147–155 (TYQRTRALV), are derived from the
amino acid sequence of A/JAPAN/305/57 hemagglutinin (HA) or
nucleocapsid (NP) proteins and are recognized in association with
H-2Kd by CD8+ T cells following infection with A/JAPAN/305/57.
M282–90 (SYIGSINNI), a peptide that is derived from the RSV M2 pro-
tein and like the above influenza peptides binds to H-2Kd, was used
as a control.
Preparation of Lung and PBLN Cells
The lung vascular bed was flushed via the right ventricle with PBS
containing 10 U/ml heparin (Sigma) to eliminate any blood. Subse-
quently, the lungs and PBLN were removed, minced, and pressed
though a wire screen.
MACS CD8a+ CL-4 Cell Purification
Single-cell suspensions of splenic cells from CL-4 mice were incu-
bated with anti-CD8a microbeads and purified according to the
manufacturer’s instructions (Miltenyi Biotec).Isolation of Splenic Mononuclear Cells
Splenic cells from mice were resuspended in NycoPrep 1.077A
(Axis-Shield) and then purified according to the manufacturer’s in-
structions.
Cell Labeling
In Situ CFSE Pulmonary-Cell Staining
Pulmonary cells were labeled in situ with CFSE as previously de-
scribed (Legge and Braciale, 2003).
In Vitro Cell Labeling
MACS-purified CD8a+ T cells (107/ml) were labeled with 1 mM CFSE
for 10 min at room temperature. NycoPrep-purified splenic mono-
nuclear cells (107/ml) were labeled with either 1 mM CFSE at 37ºC
for 10 min or 2 mM PKH-26 at room temperature for 5 min. Following
labeling, residual non-cell-associated CFSE and PKH-26 were neu-
tralized by adding an equal volume of serum to the cell suspension.
Adoptive Transfer
MACS-purified CFSE+CD8+ CL-4 T cells (107) were adoptively trans-
ferred intravenously into BALB/c thy1.1+ congenic or CPt.C3-
Tnfsf6gld/J mice. Twenty-four hr later, mice were infected with influ-
enza virus as described above.
In Vivo Cytotoxicity Assay
CFSE+ splenic mononuclear cells (107/ml) were pulsed with 10 mM
HA204–212, HA529–537, and NP147–155 peptide for 1 hr at 37ºC. PKH-26
+
splenic mononuclear cells (107/ml) were similarly pulsed with 10 mM
M282–90. The cells were then washed and mixed at a 1:1 ratio, and
107 cells (i.e., 53 106 CFSE+, 53 106 PKH-26+ cells) were adoptively
transferred into influenza-virus-infected BALB/c mice. Eight hours
post transfer, the lungs were removed from the mice; digested in col-
lagenase type XI (12,500 U/ml), Hyaluronidase type I-s (60,000 U/ml),
and DNase (6,000 U/ml) for 30 min at 37ºC; fixed; and analyzed by
flow cytometry. The percentage of specific killing was then calcu-
lated ([CFSE+ cell #/PHK-26+ cell #] 3 100).
In Vitro Intact Lymph Node Culture
PBLN were harvested from naive and influenza-infected BALB/c and
CD8+ Clone-4 BALB/c-Thy1.1 adoptively transferred mice, im-
mersed in Iscove’s media 10% FCS (5 LN/500 ml), and cultured intact
for 24–48 hr at 37ºC in 95%O2/5%CO2 [modified from (Logan et al.,
1991)]. To some intact LN cultures, 50 mg of hamster anti-mouse
Fas (Jo2) (BD PharMingen), 10 mg rmFas-humanFc (R&D Systems),
100 ng rIL-12p70 (R&D Systems), 400 ng IL-12p40 homodimer (R&D
Systems), 50 mg rat anti-mouse IL-12p40 (C17.8) (BD PharMingen),
10 mg human IgG (Caltag), or 50 mg rat IgG2a (BD PharMingen)
was added. The PBLN were subsequently dissociated, and the cells
were used for further analysis. In experiments designed to measure
LN cytokine expression, five intact PBLN were removed at 24 hr PI
and cultured in 200 ml of culture media for 48 hr.
ELISA
Supernatants from intact LN cultures were analyzed in total
IL-12p40, IL-12p70, and IL-23 capture ELISAs according to the man-
ufacturer’s instructions (eBiosciences). Graded amounts of re-
combinant mouse IL-12p40, IL-12p70, or IL-23 were included in all
experiments for construction of standard curves. The cytokine con-
centration in intact-LN-culture supernatants was estimated by ex-
trapolation from the linear portion of the standard curve. Control
rIL-23 samples run on the total IL-12p40 ELISA display only 50%
of the value obtained in the IL-23 ELISA, as a result of the differing
affinities of the antibody clones for the IL-23 dimer (eBiosciences).
Therefore, 50% of the value obtained for samples within the IL-23
ELISA has been added to the results of the total IL-12p40 ELISA in
order to correct for this difference.
Flow-Cytometry Analysis
Surface Labeling
Isolated lung and PBLN cells (106) were stained with hamster anti-
mouse CD11c (HL3) conjugated to either PE or APC; rat anti-mouse
CD8a PE, PerCP-CY5.5, or APC (53-6.7); hamster anti-mouse CD95/
Fas APC (Jo2); hamster anti-mouse CD178/FasL Biotin (MFL3); rat
anti-mouse CD90.2 PE or APC (53-2.1); hamster anti-mouse CD69
PE (H1.2F3); rat anti-mouse CD25 APC (PC61); rat anti-mouse
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mouse CD86 PE (GL1); rat anti-mouse CD8b (CT-CD8b); and/or rat
anti-mouse I-A/I-E PE (M5/114.15.2). All mAb used in the FACS
staining except for rat anti-mouse CD8b (Caltag) were purchased
from BD PharMingen. Cells stained with biotinylated antibody were
subsequently incubated with Strepavidin-PerCP, Strepavidin-PE, or
Strepavidin-APC. Stained cells were fixed and erythrocyte lysed
with FACS lysing solution (BD PharMingen) and subsequently ana-
lyzed with a BDFACSCalibur flow cytometer. LDNC were identified
based on previously published criteria (Legge and Braciale, 2003).
Intracellular Cytokine Staining
Lung or PBLN cells from mice infected with influenza were cultured
at 2 3 106 cells/well in the presence of 1 mg/ml brefeldin A. The lung
cell cultures additionally included 1 mM of the above influenza pep-
tides or media control and 400 U/ml recombinant human IL-2. After
6 hr, cells were harvested, stained with rat anti-mouse CD8b PE or
hamster anti-mouse CD11c PE (HL3), fixed, permeablized, and
stained with either rat anti-mouse IFNg APC (XMG1.2) or rat anti-
mouse IL-12p40 APC (C15.6).
Influenza-Protein Staining
PBLN cells were fixed, permeablized, and stained sequentially with
hamster anti-mouse CD11c (HL3) PE, mouse anti-HA (FC125), mouse
anti-NP (H16-L10-4R5, a kind gift of Walter Gerhard, Wistar Institute,
University of Pennsylvania), biotinylated mouse anti-NP, and/or bio-
tinylated mouse anti-NS1 (1A7, a kind gift of Jonathan Yewdell, Lab-
oratory of Viral Diseases, NIAID). Uncoupled primary antibodies
were reveled with goat anti-mouse IgG APC (Caltag) prior to staining
with biotinylated antibodies. The biotin-coupled antibodies were
subsequently reveled with Strepavidin-PerCP.
Apoptosis Staining
Isolated PBLN and lung cells were stained with rat anti-mouse
CD90.2 PE, washed twice in PBS, and then resuspended in 13 An-
nexin V binding buffer at 106 cells/ml and stained with Annexin
V-APC and 7-AAD according to the manufacturer’s instructions
(BD PharMingen).
Supplemental Data
Supplemental Data include three figures and are available with this
article online at: http://www.immunity.com/cgi/content/full/23/6/
649/DC1/.
Acknowledgments
We thank Michael Basedow and Arna Katewa for technical assis-
tance. This work was supported by USPHS grants AI15608 and
HL33391 to T.J.B. and University of Iowa Department of Pathology
start-up funds and a Cancer Research Institute postdoctoral fellow-
ship to K.L.L.
Received: April 8, 2005
Revised: September 14, 2005
Accepted: November 16, 2005
Published: December 13, 2005
References
Aoki, K., Kurooka, M., Chen, J.J., Petrynaik, J., Nabel, E.G., and
Nabel, G.J. (2001). Extracellular matrix interacts with soluble
CD95L: Retention and enhancement of cytoxicity. Nat. Immunol. 2,
333–337.
Bajenoff, M., Granjeaud, S., and Guerder, S. (2003). The strategy of
T cell antigen-presenting cell encounter in antigen-draining lymph
nodes revealed by imaging of initial T cell activation. J. Exp. Med.
198, 715–724.
Belz, G.T., Smith, C.M., Kleinert, L., Reading, P., Brooks, A., Short-
man, K., Carbone, F.R., and Heath, W.R. (2004). Distinct migrating
and nonmigrating dendritic cell populations are involved in MHC
class I-restricted antigen presentation after lung infection with virus.
Proc. Natl. Acad. Sci. USA 101, 8670–8675.
Bhardwaj, N., Seder, R.A., Reddy, A., and Feldman, M.V. (1996).
IL-12 in conjunction with dendritic cells enhances antiviral CD8+
CTL responses in vitro. J. Clin. Invest. 98, 715–722.D’Andrea, A., Rengaraju, M., Valiante, N.M., Chehimi, J., Kubin, M.,
Aste, M., Chan, S.H., Kobayashi, M., Young, D., Nickbarg, E., et al.
(1992). Production of natural killer cell stimulatory factor (interleukin
12) by peripheral blood mononuclear cells. J. Exp. Med. 176, 1387–
1398.
Eichelberger, M., Allan, W., Zijlstra, M., Jaenisch, R., and Doherty,
P.C. (1991). Clearance of influenza virus respiratory infection in
mice lacking class I major histocompatibility complex-restricted
CD8+ T cells. J. Exp. Med. 174, 875–880.
Gavrilescu, L.C., and Denkers, E.Y. (2003). Interleukin-12 p40- and
Fas ligand-dependent apoptotic pathways involving STAT-1 phos-
phorylation are triggered during infection with a virulent strain of
Toxoplasma gondii. Infect. Immun. 71, 2577–2583.
Germain, R.N., and Jenkins, M.K. (2004). In vivo antigen presenta-
tion. Curr. Opin. Immunol. 16, 120–125.
Gillessen, S., Carvajal, D., Ling, P., Podlaski, F.J., Stremlo, D.L.,
Familletti, P.C., Gubler, U., Presky, D.H., Stern, A.S., and Gately,
M.K. (1995). Mouse interleukin-12 (IL-12) p40 homodimer: A potent
IL-12 antagonist. Eur. J. Immunol. 25, 200–206.
Graham, M.B., and Braciale, T.J. (1997). Resistance to and recovery
from lethal influenza virus infection in B lymphocyte-deficient mice.
J. Exp. Med. 186, 2063–2068.
Green, D.R., and Ferguson, T.A. (2001). The role of Fas ligand in im-
mune privilege. Nat. Rev. Mol. Cell Biol. 2, 917–924.
Gretz, J.E., Anderson, A.O., and Shaw, S. (1997). Cords, channels,
corridors and conduits: Critical architectural elements facilitating
cell interactions in the lymph node cortex. Immunol. Rev. 156, 11–24.
Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigor-
ena, S. (2002). Antigen presentation and T cell stimulation by den-
dritic cells. Annu. Rev. Immunol. 20, 621–667.
Heinzel, F.P., Hujer, A.M., Ahmed, F.N., and Rerko, R.M. (1997).
In vivo production and function of IL-12p40 homodimers. J. Immu-
nol. 158, 4381–4388.
Holscher, C. (2004). The power of combinatorial immunology: IL-12
and IL-12-related dimeric cytokines in infectious diseases. Med.
Microbiol. Immunol. (Berl.) 193, 1–17.
Holscher, C., Atkinson, R.A., Arendse, B., Brown, N., Myburgh, E.,
Alber, G., and Brombacher, F. (2001). A protective and agonistic
function of IL-12p40 in mycobacterial infection. J. Immunol. 167,
6957–6966.
Juedes, A.E., and von Herrath, M.G. (2003). Using regulatory APCs to
induce/maintain tolerance. Ann. N Y Acad. Sci. 1005, 128–137.
Katakai, T., Hara, T., Lee, J.H., Gonda, H., Sugai, M., and Shimizu, A.
(2004). A novel reticular stromal structure in lymph node cortex: An
immuno-platform for interactions among dendritic cells, T cells
and B cells. Int. Immunol. 16, 1133–1142.
Kawashima, T., Kawasaki, H., Kitamura, T., Nojima, Y., and Mori-
moto, C. (1998). Interleukin-12 induces tyrosine phosphorylation of
an 85-kDa protein associated with the interleukin-12 receptor beta
1 subunit. Cell. Immunol. 186, 39–44.
Lawrence, C.W., and Braciale, T.J. (2004). Activation, differentiation,
and migration of naive virus-specific CD8+ T cells during pulmonary
influenza virus infection. J. Immunol. 173, 1209–1218.
Lee, S.W., Park, Y., Yoo, J.K., Choi, S.Y., and Sung, Y.C. (2003). In-
hibition of TCR-induced CD8 T cell death by IL-12: Regulation of
Fas ligand and cellular FLIP expression and caspase activation by
IL-12. J. Immunol. 170, 2456–2460.
Legge, K.L., and Braciale, T.J. (2003). Accelerated migration of re-
spiratory dendritic cells to the regional lymph nodes is limited to
the early phase of pulmonary infection. Immunity 18, 265–277.
Lindquist, R.L., Shakhar, G., Dudziak, D., Wardemann, H., Eisen-
reich, T., Dustin, M.L., and Nussenzweig, M.C. (2004). Visualizing
dendritic cell networks in vivo. Nat. Immunol. 5, 1243–1250.
Logan, A.C., Chow, K.P., George, A., Weinstein, P.D., and Cebra, J.J.
(1991). Use of Peyer’s patch and lymph node fragment cultures to
compare local immune responses to Morganella morganii. Infect.
Immun. 59, 1024–1031.
Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J. (1994). Cyto-
lytic T-cell cytotoxicity is mediated through perforin and Fas lytic
pathways. Nature 370, 650–652.
FasL+ DC Regulation of Viral CD8 T Cell Immunity
659Lu, L., Qian, S., Hershberger, P.A., Rudert, W.A., Lynch, D.H., and
Thomson, A.W. (1997). Fas ligand (CD95L) and B7 expression on
dendritic cells provide counter-regulatory signals for T cell survival
and proliferation. J. Immunol. 158, 5676–5684.
Magram, J., Sfarra, J., Connaughton, S., Faherty, D., Warrier, R.,
Carvajal, D., Wu, C.Y., Stewart, C., Sarmiento, U., and Gately, M.K.
(1996). IL-12-deficient mice are defective but not devoid of type 1 cy-
tokine responses. Ann. N Y Acad. Sci. 795, 60–70.
Mellman, I., and Steinman, R.M. (2001). Dendritic cells: Specialized
and regulated antigen processing machines. Cell 106, 255–258.
Morgan, D.J., Liblau, R., Scott, B., Fleck, S., McDevitt, H.O., Sarvet-
nick, N., Lo, D., and Sherman, L.A. (1996). CD8(+) T cell-mediated
spontaneous diabetes in neonatal mice. J. Immunol. 157, 978–983.
Moser, M. (2003). Dendritic cells in immunity and tolerance- do they
display opposite functions? Immunity 19, 5–8.
Norbury, C.C., Basta, S., Donohue, K.B., Tscharke, D.C., Princiotta,
M.F., Berglund, P., Gibbs, J., Bennink, J.R., and Yewdell, J.W.
(2004). CD8+ T cell cross-priming via transfer of proteasome sub-
strates. Science 304, 1318–1321.
Oh, S., and Eichelberger, M.C. (2000). Polarization of allogeneic
T-cell responses by influenza virus-infected dendritic cells. J. Virol.
74, 7738–7744.
Presky, D.H., Yang, H., Minetti, L.J., Chua, A.O., Nabavi, N., Wu, C.Y.,
Gately, M.K., and Gubler, U. (1996). A functional interleukin 12 recep-
tor complex is composed of two beta-type cytokine receptor sub-
units. Proc. Natl. Acad. Sci. USA 93, 14002–14007.
Russell, T.D., Yan, Q., Fan, G., Khalifah, A.P., Bishop, D.K., Brody,
S.L., and Walter, M.J. (2003). IL-12p40 homodimer-dependent mac-
rophage chemotaxis and respiratory viral inflammation are mediated
through IL-12 receptor beta 1. J. Immunol. 171, 6866–6874.
Suss, G., and Shortman, K. (1996). A subclass of dendritic cells kills
CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 183,
1789–1796.
Topham, D.J., Tripp, R.A., and Doherty, P.C. (1997). CD8+ T cells
clear influenza virus by perforin or Fas-dependent processes. J. Im-
munol. 159, 5197–5200.
Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resis-
tance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146.
Valenzuela, J., Schmidt, C., and Mescher, M. (2002). The roles of
IL-12 in providing a third signal for clonal expansion of naive CD8
T cells. J. Immunol. 169, 6842–6849.
Wolfe, T., Asseman, C., Hughes, A., Matsue, H., Takashima, A., and
von Herrath, M.G. (2002). Reduction of antiviral CD8 lymphocytes in
vivo with dendritic cells expressing Fas ligand-increased survival of
viral (lymphocytic choriomeningitis virus) central nervous system in-
fection. J. Immunol. 169, 4867–4872.
Wu, B., Wu, J.M., Miagkov, A., Adams, R.N., Levitsky, H.I., and
Drachman, D.B. (2001). Specific immunotherapy by genetically engi-
neered APCs: The ‘‘guided missile’’ strategy. J. Immunol. 166, 4773–
4779.
Zinkernagel, R.M. (1996). Immunology taught by viruses. Science
271, 173–178.
Zou, J., Presky, D.H., Wu, C.Y., and Gubler, U. (1997). Differential as-
sociations between the cytoplasmic regions of the interleukin-12 re-
ceptor subunits beta1 and beta2 and JAK kinases. J. Biol. Chem.
272, 6073–6077.
